Abstract
Non-replicating persistence (NRP) is a functional adaptation that mycobacteria undergo in response to the stresses of the granuloma, facilitating antibiotic tolerance and long-term infection. These stresses, or NRP-inducing factors, include hypoxia, nutrient deprivation, and nitric oxide assault, which mycobacteria are well evolved to tolerate through a series of metabolic and physiological adaptations producing the NRP state. Most attempts to replicate these conditions in vitro have focused on only one of these factors at a time for ease and simplicity, but as a result, do not necessarily produce physiologically relevant phenotypes. Here, we provide the methods for two different in vitro NRP strategies that are useful for drug susceptibility testing and high-throughput screening.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wayne LG, Sohaskey CD (2001) Nonreplicating persistence of Mycobacterium Tuberculosis. Annu Rev Microbiol 55:139–163
Gibson SER, Harrison J, Cox JAG (2018) Modelling a silent epidemic: a review of the in vitro models of latent tuberculosis. Pathogens 7(4):88. https://doi.org/10.3390/pathogens7040088
Martin CJ, Carey AF, Fortune SM (2016) A bug’s life in the granuloma. Semin Immunopathol 38:213–220
Parish T, Stoker NG, Wayne LG (2003) In vitro model of hypoxically induced nonreplicating persistence of Mycobacterium tuberculosis. Methods Mol Med 54:247–269. https://doi.org/10.1385/1-59259-147-7:247
Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43:717–731
Wipperman MF, Sampson NS, Thomas ST (2014) Pathogen roid rage: cholesterol utilization by Mycobacterium tuberculosis. Crit Rev Biochem Mol Biol 49:269–293
Voskuil MI, Schnappinger D, Visconti KC et al (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198:705–713
Griffin JE, Pandey AK, Gilmore SA et al (2012) Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptations. Chem Biol 19:218–227
Schnappinger D, Ehrt S, Voskuil MI et al (2003) Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the Phagosomal environment. J Exp Med 198(5):693–704. https://doi.org/10.1084/jem.20030846
Houben RMGJ, Dodd PJ (2016) The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 13:e1002152
WHO (2019) Global TB Rep 2019
Wayne LG, Hayes LG (1996) An in vitro model for sequential study of Shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64(6):2062–2069
Cho SH, Goodlett D, Franzblau S (2006) ICAT-based comparative proteomic analysis of non-replicating persistent Mycobacterium tuberculosis. Tuberculosis 86:445–460
Dickinson JM, Aber VR, Mitchison DA (1977) Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am Rev Respir Dis 116:627–635
Cho SH, Warit S, Wan B et al (2007) Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 51:1380–1385
Amsterdam D (2005) Susceptibility testing of antimicrobials in liquid media. In: Lorian V (ed) Antibiotics in laboratory medicine, 5th edn. Lippincott Williams & Wilkins, PA, USA
Velayati AA, Farnia P, Masjedi MR et al (2011) Sequential adaptation in latent tuberculosis bacilli: observation by atomic force microscopy (AFM). Int J Clin Exp Med 4:193–199
Jakkala K, Ajitkumar P (2019) Hypoxic non-replicating persistent Mycobacterium tuberculosis develops thickened outer layer that helps in restricting rifampicin entry. Front Microbiol 10:2339
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Gibson, S.E.R., Harrison, J., Cox, J.A.G. (2021). Drug Susceptibility Screening Using In Vitro Models of Hypoxic Non-Replicating Persistent Mycobacteria. In: Parish, T., Kumar, A. (eds) Mycobacteria Protocols. Methods in Molecular Biology, vol 2314. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1460-0_10
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1460-0_10
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1459-4
Online ISBN: 978-1-0716-1460-0
eBook Packages: Springer Protocols